CMPS:NSD-Compass Pathways Plc (USD)

COMMON STOCK | Medical Care Facilities |

Last Closing

USD 6.81

Change

0.00 (0.00)%

Market Cap

USD 0.50B

Volume

0.24M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-28 )

Largest Industry Peers for Medical Care Facilities

Symbol Name Price(Change) Market Cap
ENSG The Ensign Group Inc

N/A

USD 8.62B
ACHC Acadia Healthcare Company Inc

N/A

USD 5.88B
OPCH Option Care Health Inc

N/A

USD 5.37B
SGRY Surgery Partners Inc

N/A

USD 4.06B
AMED Amedisys Inc

N/A

USD 3.16B
LFST Lifestance Health Group Inc

N/A

USD 2.66B
ASTH Astrana Health Inc

N/A

USD 2.58B
ADUS Addus HomeCare Corporation

N/A

USD 2.37B
AVAH Aveanna Healthcare Holdings In..

N/A

USD 1.00B
HCSG Healthcare Services Group Inc

N/A

USD 0.81B

ETFs Containing CMPS

PSIL AdvisorShares Psychedelic.. 6.47 % 0.00 %

N/A

USD 4.53M
PSY 0.00 % 0.76 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Care Facilities) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -22.17% 54% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.17% 54% F 28% F
Trailing 12 Months  
Capital Gain -7.97% 60% D- 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.97% 60% D- 34% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -26.38% N/A N/A 13% F
Dividend Return -26.38% N/A N/A 13% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.69% N/A N/A 64% D
Risk Adjusted Return -91.95% N/A N/A 7% C-
Market Capitalization 0.50B 58% F 61% D-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector